Menopur

Menotropin, the active ingredient in Menopur, is a gonadotropin (FSH/LH) preparation presented as a powder for solution for injection for subcutaneous use. It treats infertility by stimulating follicular development in anovulatory women and enhancing spermatogenesis in men with hypogonadotropic hypogonadism.

GNH USA supplies Menopur as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our global distribution network ensures consistent quality and regulatory compliance, enabling healthcare providers to access the product for reproductive medicine programs across Europe, Asia, Africa and the Americas.

Menopur is used in reproductive medicine to modulate gonadotropin pathways for infertility treatment. - Anovulatory infertility: induces ovulation in women who do not ovulate spontaneously, facilitating natural or assisted conception. - Assisted reproductive technology cycles: supports controlled ovarian hyperstimulation for in‑vitro fertilisation, ICSI and embryo transfer procedures. - Male hypogonadotropic hypogonadism: stimulates spermatogenesis in men with deficient FSH/LH production, improving sperm output.

Menopur may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Injection site pain: mild discomfort or erythema at the injection site. - Abdominal bloating: transient abdominal distension or discomfort. - Headache: mild to moderate headache episodes. - Ovarian hyperstimulation symptoms: mild abdominal discomfort, nausea, or mild weight gain.

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome (OHSS): severe ovarian enlargement, fluid shift, and thromboembolic risk. - Multiple pregnancy: increased chance of twins or higher-order gestations. - Allergic reaction: rash, urticaria, or anaphylaxis.

Prior to initiating Menopur, clinicians should evaluate patient history and monitor specific parameters to minimise risks. - Baseline ovarian assessment: perform ultrasound to determine follicle count and size. - Hormone monitoring: regularly measure serum estradiol and LH/FSH levels during treatment. - OHSS risk evaluation: assess risk factors such as polycystic ovary syndrome or high antral follicle count. - Pregnancy testing: confirm absence of pregnancy before starting therapy. - Concomitant medication review: avoid drugs that may exacerbate ovarian response or interact with gonadotropins. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Menopur can interact with other agents that affect hormonal balance or ovarian response.

Major Interactions (Avoid): - GnRH agonists/antagonists: concurrent use may cause excessive ovarian stimulation. - Aromatase inhibitors: may blunt estrogen response and reduce efficacy.

Moderate Interactions (Monitor Closely): - Clomiphene citrate: combined use may increase risk of OHSS, requiring dose adjustment. - Anticoagulants: monitor for thrombotic events if OHSS develops. - Thyroid hormone therapy: ensure euthyroid status as thyroid imbalance can affect response.